Proactiveinvestors United Kingdom Sativa Investments Proactiveinvestors United Kingdom Sativa Investments RSS feed en Wed, 20 Mar 2019 05:11:53 +0000 Genera CMS (Proactiveinvestors) (Proactiveinvestors) <![CDATA[News - Sativa Investments brings in expert to aid its move into the CBD veterinary market ]]> Sativa Investments PLC (NEX:SATI), the UK’s first medicinal cannabis investment vehicle, has appointed veterinary expert Dr Nick Horniman as its new director of regulatory affairs.

Horniman has thirty years' experience in the veterinary industry and spent more than twenty of those running a group of private veterinary practices which he has since sold.

His appointment fits in nicely with Sativa’s move into the veterinary market, which it announced last month.

READ: Sativa unveils ambitious new strategic blue-print

As part of his new senior management role, Horniman’s job will be to explore the use of cannabis-based treatments in animals.

He will also be tasked with liaising with the relevant agencies to establish CBD regulation and progress Sativa's medicinal cannabis Growing Licence application.

“As announced in [January], Sativa is planning to enter the potentially lucrative CBD veterinary market through Sativa Veterinary services,” said Sativa chief executive Geremy Thomas.

“The CBD veterinary market has already taken off in North America and Dr Horniman will also advise on how best to go about launching the veterinary arm in the UK.

Horniman has been granted options over 3.1mln shares in the company with an exercise of 6.5p per share.

Sativa shares closed at 5.25p on Friday afternoon.

Mon, 11 Feb 2019 08:00:00 +0000
<![CDATA[News - Sativa Investments appoints head of new retail arm ]]> Sativa Investments PLC (NEX:SATI) has appointed Chris Jones to launch wellness centres that will sell a medicinal range of cannabis-derived products.

Retail professional Jones most recently held the role of consultant sales director at a vaping company with 110 outlets and worked with another in Northern Ireland with 20 stores.

WATCH: Sativa Investments 'at the forefront' of developing UK medical cannabis market

Before that, he had senior positions in the mobile phone industry with names such as Nokia, where he was UK sales director, Dextra Mobile Accessories and Phones 4U. 

Jones, who will be the managing director of Sativa Wellness Centres Limited, helped build Swindon-based mobile service provider Cellular Operations to a subscriber base of 500,000 before it was acquired by Vodafone.

“Chris' experience of growing businesses in these highly competitive markets, coupled with very strong retail and franchise operational knowledge, is an ideal fit for Sativa's aggressive market development plans for its Goodbody & Blunt wellness centres,” said founder and chief executive Geremy Thomas.

“The model will be proofed with two to three retail outlets, then the company has the option to roll it out further or as a franchise.”

CBD products 

The aforementioned Goodbody & Blunt will offer customers a variety of cannabidiol, or CBD wellness products at drop-in cafes.

CBD is a cannabis compound that is thought to have significant medical benefits, but does not make people feel “stoned”.

The fact that CBD-rich cannabis is non-psychoactive or less psychoactive than THC-dominant strains makes it an appealing option for people looking for relief from inflammation, pain and anxiety.

Earlier this month, NEX-listed Sativa, which was set up as a vehicle to invest in medicinal cannabis, announced plans to become a first-mover seed-to-consumer business here in the UK, following the model pioneered in Canada.

Its blueprint will require at least £12mln of funding – which would cover the cost of a glasshouse operation in Wiltshire – and probably more if it is to fully bankroll its ambitious plans.

In afternoon trading, Sativa Investments shares on the NEX market were trading at a mid-price of 5.875p each, up from Monday's close of 5.65p.

 -- Adds share price --

Tue, 15 Jan 2019 08:04:00 +0000
<![CDATA[Media files - Sativa Investments 'at the forefront' of developing UK medical cannabis market ]]> Thu, 10 Jan 2019 13:55:00 +0000 <![CDATA[News - Sativa Investments unveils ambitious new strategic blue-print ]]> Sativa Investments PLC (LON:SATI), the NEX-based medical cannabis investor, has unveiled plans to become a first-mover seed-to-consumer business in the UK.

Its blueprint will require at least £12mln of funding – which would cover the cost of a glasshouse operation in Wiltshire – and probably more if it is to fully bankroll its ambitious blueprint.

READ: Sativa Investments' investee firm Rapid Dose Therapeutics begins trading on CSE

Sativa is taking its cue from Canada, which first approved the drug for medical use 18 years ago, and is now home to vertically integrated cannabis giants such as Canopy Growth (now listed in New York and worth just shy of US$10bn).

Also revealed in the strategic update was the company’s desire to advance its venture with Lexamed of Germany to provide a distribution channel for its medicinal cannabis and cannabinol, or CBD products.

Wellness retail centres

Also under consideration, are CBD wellness retail centres and clinics and the group will assess the potential veterinary use of the ‘herb’.

Sativa said there had been a change of sentiment in the UK towards the industry from the regulators, government and the medical profession.

There is a growing belief among these groups that the drug may have a role to play in areas such as pain relief that avoids the use of addictive opioids.  

Hemp success

“The company's operations now cover seed growing, in so far as the company has already successfully grown a hemp crop under the CEO's own growers' licence, and along with great strides in developing its medical cannabis business, and has researched, tested, marketed and sold CBD products,” explained Geremy Thomas, Sativa’s founder and chief executive.

"Sativa now has a solid base on which to build its seed-to-consumer model and this next round of fundraising will allow institutions and other investors to participate in what is expected to be a major UK industry."

Listed on the NEX exchange less than nine months ago, Sativa was set up to make investments into Canada-based or dual-listed cannabis companies.

It has so far ploughed cash into six early-stage businesses, including Veritas Pharma and George Botanicals.

Tue, 08 Jan 2019 07:50:00 +0000
<![CDATA[News - Sativa Investments' investee firm Rapid Dose Therapeutics begins trading on CSE ]]> Bio-technology firm Rapid Dose Therapeutics Inc (CSE:DOSE), an investee business of medicinal cannabis investor Sativa Investments PLC (LON:SATI), has been admitted to trading on the Canadian Stock Exchange.

Sativa Investments, which is the UK’s first medicinal cannabis investment firm, subscribed for 400,000 shares at C$50 each in Rapid Dose Therapeutics for C$200,000 in cash ahead of the listing on Monday.

At the close on Monday, shares were trading hands at C$0.85 each.

WATCH: Sativa Investments 'at the forefront' of developing UK medical cannabis market

Rapid Dose Therapeutics has developed a fast-dissolving medicinal cannabis strip, called Quickstrip, that is placed on or under the tongue, or inside the cheek. The company also sells pharmaceuticals, emulsified oils and over-the-counter medicines across North America.

The firm has made an initial paper profit of C$140,000 for Savita Investments, an increase of 70%, after just seven months.

"RDT's technology has very positive implications for both Sativa's medicinal cannabis business and its CBD (cannabidiol) focused 100% subsidiary George Botanicals Limited, and we look forward to continued collaboration with RDT alongside our investment." 

Tue, 18 Dec 2018 07:29:00 +0000
<![CDATA[News - Award-winning pain consultant appointed to Sativa Investments’ advisory board ]]> Sativa Investments PLC (NEX:SATI) has appointed an award-winning pain medicine and anaesthetic consultant to its medical cannabis advisory board.

Matthew Brown is a consultant at the Royal Marsden hospital in West London and recently published research into using cannabinoids for cancer pain treatment.

READ: Sativa announces £3.75mln equity raise

Last month, the UK government gave doctors the green light to prescribe cannabis products to patients for the first time ever.

“The new Home Office guidelines determining the prescription of Medicinal Cannabis encompass the treatment of pain and nausea in cancer patients,” said founder and chief executive Geremy Thomas.

“Matthew's qualifications and research in this area add even further to the input of Sativa's top-level Medicinal Cannabis Advisory Board. Patient outcome is the clear driver in the highly sensitive and prevalent area of cancer treatment.”

Thu, 06 Dec 2018 08:37:00 +0000
<![CDATA[News - Sativa's George Botanicals division expands range of CBD products ]]> George Botanicals, the CBD products maker owned by Sativa Investments PLC (LON:SATI) has launched a balm and expanded its range of drinkable oils infused with the cannabinoid extract.

Demand for CBD products is growing due to their perceived health and well-being benefits that include pain and stress relief.

READ: Sativa Investments announces £3.75mln equity raise and plans to build UK cannabis greenhouse

The new balm contains one per cent of CBD, while the MCT oils have a five per cent concentration of CBD and derive from coconut oil, making it easy to mix with beverages and soft drinks. 

Natural CBD products are thought to boost internal cannabinoids in a similar way to vitamin supplements. 

MCT oils can also be placed under the tongue for instant flavour and fast absorption.

George Thomas, managing director, said: "CBD has become increasingly popular in the past few months as customers become aware of its associated health and well-being benefits.

The balm will retail for £24.99 and the MCT oils for £29.99.

Nex-listed Sativa acquired George Botanicals in June for £415,000.

Wed, 28 Nov 2018 08:41:00 +0000
<![CDATA[News - Sativa Investments announces £3.75mln equity raise and plans to build UK cannabis greenhouse ]]> UK medicinal cannabis investment vehicle Sativa Investments PLC (LON:SATI) said it has raised £3.75mln in a share placing and signed heads of terms for a £85,000 option to lease a 7.53 acre development site in Wiltshire.  

The company said it placed 62.5mln new ordinary shares at 6p each and the proceeds of the equity raise would be used to “further Sativa’s progress and development as the UK’s first medicinal cannabis investment vehicle”.

READ: Sativa Investments moves into Germany, one of Europe’s largest medical cannabis markets

Sativa expects the option agreement on the Wiltshire site to be signed today after which it plans to construct a glasshouse on up to 6.86 acres. The site will be used to grow cannabis plants for the production of medicinal cannabis and cannabidiol (CBD) products. An extraction facility and offices will also be built on the site.

The group has been granted planning permission to build the glasshouse. It will enter into a 25-year term lease for the site and will be able to extend this for a further three months for a £15,000 payment under an option that can be exercised at any time up to July 2019.  

Sativa on track to become UK's first seed to consumer medicinal cannabis business

The move is part of the company’s plans to become the UK’s first seed to consumer medicinal cannabis business. Sativa already has a cannabis-testing laboratory in the UK, called PhytoVista Laboratories, and its subsidiary George Botanicals has a UK hemp growers' licence.

Sativa said the cost of the 7.53-acre site, including the construction of the glasshouse, an extraction facility and offices, is estimated to be £10.5mln.

READ: Medicinal cannabis investor Sativa Investments reports 'significant progress' post IPO Sativa to offer products at 'highly competitive rates'

The glasshouse will sit beside an existing 3.6MW capacity bio-digester plant from which the company will be able to purchase electricity at significantly below market rates. This will make it the first green-powered medicinal cannabis canopy in the UK.

“The directors believe that this in turn will enable Sativa to offer products to the market at highly competitive rates,” the company said.

The company said about 194,224 sq ft or 65% of the 298,806 sq ft glasshouse will be harvested while the rest will be used for ancillary space including walkways and seedlings.

Industry figures show that each square foot of canopy produces 40 grams of raw cannabis, which had an average wholesale gross revenue of £4.00 per gram in the last year.

Canadian-based Veritas Pharma Inc. is advising Sativa on cannabis strain selection.

As part of the consideration for the option, Sativa will offer owners of the farm an option to acquire 2 million ordinary shares in the company at a price of 5 pence per share after the development is completed and operational. 

The announcement comes after the UK government said doctors will be able to prescribe medicinal cannabis from November 1.

READ: Recreational pot: Where in the world is it legal and will the UK ever approve?

People suffering from chronic pain, epilepsy, or nausea as a result of chemotherapy or multiple sclerosis (MS) will be among the first to be prescribed the drugs.

Thu, 18 Oct 2018 12:57:00 +0100
<![CDATA[News - Medical cannabis to be available in UK on prescription by start of November ]]> Medicinal cannabis products, used in the treatment of various conditions that cause chronic pain, will be available on prescription to patients from the start of next month following a rescheduling of the drug by UK Home Secretary Sajid Javid.

People suffering from chronic pain, epilepsy, or nausea as a result of chemotherapy or multiple sclerosis (MS) will be among the first to be prescribed the drugs, which marks a turning point in the push to legalise cannabis products in the UK.

READ: Medicinal cannabis investor Sativa Investments reports 'significant progress' post IPO

At the moment, cannabis-derived can only be prescribed in exceptional circumstances after permission is granted by a panel of medical experts, although the Home Office will relax the rules from 1 November.

The policy change follows an incident in June when 12-year old Billy Caldwell had his cannabis oil, prescribed to alleviate the symptoms of epilepsy, confiscated at Heathrow Airport, a decision that was only reversed when an emergency permit was issued by the government.

However, Geremy Thomas, chief executive and founder of medical cannabis company Sativa Investments PLC (NEX:SATI) said last week that the move by the government is not an indicator that the legalisation of recreational marijuana is in the offing.

Instead, Thomas says things will “become clearer” regarding the details of how the medical cannabis industry in the UK will take shape.

He adds that existing manufacturers outside the UK will likely be awarded limited export licenses for medical cannabis products, with investors “becoming more aware” of the scale of the industry.

“[Investors] will recognise that we [the UK] will be a very significant cannabis market,” he says.

Mon, 08 Oct 2018 15:39:00 +0100
<![CDATA[News - Medicinal cannabis investor Sativa Investments reports 'significant progress' post IPO ]]> Sativa Investments PLC (NEX:SATI), the UK’s first medicinal cannabis investment vehicle, said it has “progressed significantly” since it began trading on the NEX Exchange earlier this year.

The firm raised £1.1mln net of expenses in its initial public offering on March 29 and secured a further £500,000 in June from the LF Miton UK Smaller Companies Fund, its first major institutional investor. Founder and chief executive, Geremy Thomas, and his family invested £560,000 in the company in January. 

In the six months ended June 30, the group has invested £656,000 into Veritas Pharma Inc, Rapid Dose Therapeutics Inc and George Botanicals Ltd.

READ: Sativa Investment moves into Germany, one of Europe’s largest medical cannabis markets

As a newly established investment vehicle, Sativa generated consolidated revenues of £7,700 for the period, reflecting six days of sales by George Botanicals from its acquisition on June 22. Since the period end to August 31, George Botanicals' revenues stood at £68,200.

The group ended the first half with total consolidated assets of £2.08mln and cash at bank and cash equivalents of £1.42mln. Gross profit came to £6,700. 

In July, the company bought UK testing laboratory, PhytoVista Laboratories Ltd, for £460,000. Sativa said the acquisition will allow it meet the need for regulatory and batch testing of cannabidiol (CBD) products and, once approved by the UK Home Office, medicinal cannabis treatments including tetrahydrocannabinol (THC).

Last week Sativa said it had entered into a joint venture with German-based Lexamed GmbH ("Lexamed"), forming a new German medicinal cannabis company named Sativa Germany GmbH ("Sativa Germany"), which will secure German wholesale, import and export licences for the distribution of medicinal cannabis products.

"Sativa has progressed significantly since listing, along with the industry itself, witnessing a sea-change in attitude from the medical profession and also the government in relation to unmet patient needs and widespread realisation that the UK is falling behind in terms of accepting the benefits of medicinal cannabis,” said Thomas.

"The company continues to build a solid foundation for the end-to-end supply of medical cannabis and CBD products to fulfil its seed to consumer strategy." 

Looking ahead, Sativa expects to benefit from being the UK’s first medicinal cannabis investment vehicle as the market develops.

Thu, 27 Sep 2018 09:44:00 +0100
<![CDATA[News - Sativa Investments moves into Germany, one of Europe’s largest medical cannabis markets ]]> Cannabis investment vehicle Sativa Investments PLC (NEX:SATI) is moving into Germany as it looks to exploit the growing demand for cannabinoid products in the country.

Germany is one of the largest medical cannabis markets in Europe following the government’s decision to approve its use by prescription last year.

READ: Sativa positions itself for ‘huge opportunity’ in medicinal cannabis

Sativa has formed a joint venture with Germany-based Lexamed which will secure German wholesale, import and export licences for the distribution of medicinal cannabis products.

The long-term plan is for the products sold by the newly established Sativa Germany to be supplied by Sativa’s UK arm.

That is subject to the company successfully applying for a Home Office Medicinal Cannabis licence, so for the time being the joint venture will source products from any jurisdiction where it is regulatorily accepted.

A Sativa office is being set up in Stuttgart which will sell CBD products supplied by its subsidiary, George Botanicals.

Sative is initially investing €80,000 into the joint venture, which will give it a 60% majority shareholding. This figure could rise up to €250,000 once the German licence has been granted.

‘Important step’

“Initially, Sativa Germany has secured office space in Stuttgart and are actively recruiting sales staff to exploit the growing demand for CBD products in Germany,” said chief executive and founder Geremy Thomas.

“Once regulatory compliances are met, Sativa will supply top quality medicinal cannabis products to the German market.”

He added: “This is an important step for the Company, as it allows an entry point into the key German market to help continue its seed to consumer strategy.”

Fri, 21 Sep 2018 07:24:00 +0100
<![CDATA[News - Sativa Investments decides the time is right to appoint a full-time finance head ]]> Sativa Investments PLC (LON:SATI), the UK's first medicinal cannabis investment vehicle, has appointed former WPP man Joseph Colliver as its chief financial officer.

Colliver is a qualified chartered accountant with significant management consulting experience. Before joining Sativa, Joseph was a director of consulting at Kantar Consulting, which is part of marketing and advertising leviathan WPP.

READ: Sativa Investments inks IP deal with Canada's Veritas Pharma​

"Joseph brings a depth of international experience including from his time at Kantar Consulting, part of WPP PLC, where he advised clients on developing commercial capability,” said Geremy Thomas, the founder and chief executive officer of Sativa.

“Coupled with his experience as chief financial officer at Kantar Futures, a consultancy business with a US$32 million turnover, his role as global commercial director of WPP's Kantar subsidiary Taylor Nelson Sofres, a US$1.8 billion turnover marketing agency, and his Mazars' Accountancy training, Joseph has a lot to offer the ever-expanding Sativa," Thomas said.

Thomas said that, with four investments under its belt thus far and a pipeline of potential investments, it was time for Sativa to appoint “an experienced, strategically-thinking full-time finance head”.


Thu, 30 Aug 2018 10:01:00 +0100
<![CDATA[News - Sativa Investments inks IP deal with Canada's Veritas Pharma ]]> Sativa Investments PLC (NEX:SATI) said it has signed an IP sharing agreement with Canada’s Veritas Pharma Inc, which it hopes will help its efforts in the UK’s emerging cannabis market.

The company said it will use Veritas’ cannabis strain lead selection to assist its application to the Home Office Drugs Licensing and Compliance Unit for a medicinal cannabis growing licence.

READ: Sativa Investments refines Orderly Market Agreements to improve liquidity for NEX traded shares

In May, Sativa invested C$200,000 in Veritas.

Chief executive, Geremy Thomas, said: "A key part of Sativa's strategy is to target overseas investments that can be leveraged to assist the company commercially as it participates in the industry in the UK and wider Europe.

“In this case, Veritas' scientific knowledge of seed selection will expedite a potential UK licence application to enable Sativa to grow cannabis strains for its own research and development purposes including use by recipients of grants awarded by the Sativa Foundation."

Mon, 16 Jul 2018 07:59:00 +0100
<![CDATA[News - Sativa Investments refines Orderly Market Agreements to improve liquidity for NEX traded shares ]]> Sativa Investments PLC (NEX: SATI) has moved to improve liquidity in its NEX-listed stock by agreeing to a refinement of the Orderly Market Agreements entered into at the time of its float at the end of March.

The group, the UK's first medicinal cannabis investment vehicle, said it has made the move because it is “aware of the exceptional and growing demand amongst investors to own shares in the Company.”

READ: Sativa Investments buys UK medicinal cannabis lab for £435K

All investors who subscribed for Sativa’s ordinary shares in the company at admission entered into an Orderly Market Agreement and the group’s directors of Sativa agreed, should demand arise, to exercise their allocated options and sell the resulting ordinary shares through its corporate adviser and broker, Peterhouse Capital Limited.

However, given the unprecedented demand in the market for its shares, and the desire of Sativa’s directors not to have to be the sole suppliers of stock at levels which its board believes do not reflect the long-term value of the company, it has agreed that all shareholders who are subject to the current Orderly Market Agreements will be permitted to trade in the stock.

The firm added that such trading on the NEX Exchange Growth Market will require the consent of Peterhouse, although it added such consent should not “be unreasonably withheld”.

Sativa said its directors remain subject to the Lock-In Agreements entered into on admission, but they will no longer be required to make further shares available through the exercise of their options.

Fri, 06 Jul 2018 15:09:00 +0100
<![CDATA[Media files - Sativa Investments PLC acquires UK-based PhytoVista Laboratories ]]> Tue, 03 Jul 2018 15:50:00 +0100 <![CDATA[News - Sativa Investments buys UK medicinal cannabis lab for £435K ]]> Sativa Investments PLC (NEX:SATI) has agreed to buy PhytoVista Laboratories, a UK-based lab that tests cannabis oils and hemp products, for £435,000.

The British medicinal cannabis investment vehicle will pay £235,000 in cash and £200,000 worth of shares at 0.04p per share to buy PhytoVista from Carbon Managers Limited.

READ: Sativa Investments positions itself for 'huge opportunity' in medicinal cannabis

Carbon is wholly owned by Sativa’s chief executive Geremy Thomas but he was not involved in the decision-making for the deal.

Sativa independent directors Noel Lyons and Mark Blower assessed the deal and consulted Dr. Stuart Ungar, who is a member of the company's medicinal cannabis advisory board.

Sativa said the purchase price was well below the market value of the assets and equipment acquired. If purchased new, the equipment laboratory would cost more than £580,000, the company said.

“Every batch of medicinal cannabis including CBD oil requires stringent testing, including for cannabinoids, pesticides, heavy metals and mycotoxins, along with full testing for terpenes, residual solvents and microbiology,” Blower said.

“PhytoVista provides a UK-based laboratory facility available to all jurisdictions already testing CBD products commercially, and of course able to service the UK market if and when regulatory changes hit the UK too."

PhytoVista has preferred partner status to the UK's Cannabis Trades Association for batch testing of medicinal cannabis products.

Tue, 03 Jul 2018 13:01:00 +0100
<![CDATA[News - Sativa Investments positions itself for 'huge opportunity' in medicinal cannabis ]]> Britain’s medicinal cannabis market can be larger than Canada’s if laws here change believes Geremy Thomas, chief executive of Sativa Investments PLC (LON:SATI).

At present, there is a virtual ban in the UK on any product containing Tetrahydrocannabinol or THC, the substance in marijuana/cannabis that makes you high.

WATCH: Sativa Investments has "unique" market position for UK cannabis investors

But it is a combination of THC and CBD, a pain reliever also derived from marijuana and that is legal in the UK, which gives medicinal cannabis its potency says Thomas.

In Canada, which legalised medicinal products in 2001, sales are predicted to soar to C$10bn (£5.8bn).

There are almost twice as many people in the UK so it’s fair to see the market here being considerably larger, Thomas told Proactive.

Germany is another example. Laws were relaxed in March and by June medicinal prescriptions had jumped to 5,000 per month.

“A lot of people are getting benefit from the component parts of cannabis restricted in the UK because of political campaigns in the seventies.

“Why should our [UK] patients be denied access to something that is proving to be very effective around the world.

“The market is racing away in North America and on our doorstep in Germany.”

And that’s the point of Sativa.

Shift in opinion

Initially, it will give UK investors a way into the North American markets but ultimately Thomas wants to establish a first mover position if the UK legal position changes.

Thomas is convinced there will be a change in the law, albeit it might take up to two years.

Public opinion has shifted, he says. 

High profile cases such as six year-old epileptic Alfie Dingley, whose mother had to go the Netherlands to get a cannabis oil that dramatically improved his condition, are driving a change in mood.

Thomas, a serial entrepreneur, admits his interest is financial rather than compassionate and points to a track record of being ahead of the game in his previous ventures.

His first fortune was in mobile phones just as cellular took off.

That was followed by a shift into telecoms ahead of the boom and most recently a move into consumer finance that benefited from a regulatory crackdown.

That business, George Banco, was sold for £53mln last year.

A conference in Vancouver convinced Thomas that medicinal cannabis was the place to make his next fortune.

“I was blown away by the scale and size of the investment,” he says.

Sativa a way in

EU laws prohibit direct investment into overseas companies where the operations are technically illegal within the investor’s own country, but through a vehicle such as Sativa there is a route in.

NEX-listed, the company raised £1.6mln when it went public, most of which came from Thomas himself and friends and family.

The company has made two small investments so far: Veritas a Toronto-based firm which is carrying out testing to find the optimum combinations of CBD/THC for specific ailments.

Rapid Dose Therapeutics, meanwhile, has adapted dissolving film technology to deliver cannabis oils accurately, quicker and more effectively.

Sativa is likely to assume the rights to distribute Rapid Dose’s products in the UK and Europe.

The company has invested C$200,000 in both companies, while there is a memorandum of understanding in place for a 51% stake in George Botanicals, a UK-based CBD business owned by Carbon Managers, another of Thomas’s vehicles.

While these investments are small, Thomas is not short of ambition for the company and cites UK-based but Nasdaq-listed GW Pharma, which has a market value of US$4bn.

GW is reportedly close to US approval for a cannabis-based childhood epilepsy drug Epidolex, which it might launch in Europe next year.

Spreading the word

If successful it will raise awareness of the market even more though Thomas believes a major part of his role at Sativa is to educate both the marketplace and investors about the benefits of medicinal cannabis.

It’s a role he clearly relishes.

Unlike opiates, for instance, cannabis oils deliver real benefits to patients and without doing damage to them in the process.

People written off by traditional medicines have also seen dramatic turnarounds on cannabis oil.

“The opportunity in this space is huge and the driver is that medicinal cannabis works.”


Mon, 04 Jun 2018 11:03:00 +0100
<![CDATA[Media files - Sativa Investments has "unique" market position for UK cannabis investors ]]> Wed, 23 May 2018 12:09:00 +0100 <![CDATA[News - Sativa invests in Canadian medicinal cannabis group Veritas Pharma ]]> Sativa Investments PLC (NEX:SATI) has subscribed for half a million shares in Veritas Pharma Inc (OTCMKTS:VRTHF), an emerging Canadian pharma company specialising in medicinal cannabis therapies.

The NEX-listed medicinal cannabis investment vehicle said it had subscribed for 500,000 new shares at C$0.4 per share, a total cost of C$0.2mln in cash.

WATCH: Sativa Investments has "unique" market position for UK cannabis investors

The firm said Veritas Pharma focuses on the discovery, product development and commercialisation of effective patented Medicinal Cannabis therapies which target disease conditions in the areas of chronic pain, senior long-term and palliative care.

Sativa added that Veritas, through its subsidiary company, Cannevert Therapeutics Ltd., was aiming to obtain compelling scientific evidence for healthcare professionals to utilise medicinal cannabis strains with a reliable therapeutic effect on patients.

Geremy Thomas, Sativa chief executive, said: "We are delighted to increase our portfolio of investments by, in this case, adding a pharmaceutical research and development business.

Veritas Pharma is a well-respected company in the medicinal cannabis sector with an excellent pipeline for the development of strains to treat unmet clinical needs, and is a highly suitable investment."

He added: "The investment in Veritas reflects the Company's strategy to invest in well-established companies in jurisdictions where the use of Medicinal Cannabis is regulatory accepted. Canada approved the use of medicinal cannabis in 2001."

Mon, 21 May 2018 07:57:00 +0100